

**Company announcement**

No. 13/2017

**Orphazyme A/S**Ole Maaløes Vej 3  
DK-2200 Copenhagen Nwww.orphazyme.com  
Company Registration No. 32266355

21 November 2017

**Reporting of transactions made by persons discharging managerial responsibilities in Orphazyme A/S**

Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 ("Orphazyme"), hereby notifies receipt of information regarding the following grants under Orphazyme's long-term incentive programme as further described in company announcement 8/2017:

| <b>1 Details of the Reporting Person / Closely Associated Person</b>   |   |   |
|--|---|---|
| a)   | Name  | Anders Hinsby   |
| <b>2 Reason for the notification</b>   |   |   |
| a)   | Position/status   | Chief Executive Officer   |
| b)   | Initial notification/Amendment  | Initial notification  |
| <b>3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor</b>  |   |   |
| a)   | Name  | Orphazyme A/S   |
| b)   | LEI code  | 54930025OZD2GGSQ7L42  |
| <b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b> |   |   |
| a)   | Description of the financial instrument, type of instrument and identification code | Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S<br><br>ISIN DK0060910917   |
| b)   | Nature of the transaction   | Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme |

| c)        | Price(s) and volume(s)   | <table><tr><th>Price (s)</th><th>Volume(s)</th></tr><tr><td>0</td><td>5,000 (Matching shares)</td></tr><tr><td>0</td><td>30,000 (Performance shares assuming full vesting)</td></tr></table> | Price (s) | Volume(s) | 0 | 5,000 (Matching shares) | 0 | 30,000 (Performance shares assuming full vesting) |
|-----------|--|--|-----------|-----------|---|-------------------------|---|---|
| Price (s) | Volume(s)  |  |           |           |   |                         |   |   |
| 0         | 5,000 (Matching shares)  |  |           |           |   |                         |   |   |
| 0         | 30,000 (Performance shares assuming full vesting)  |  |           |           |   |                         |   |   |
| d)        | Aggregated information <ul style="list-style-type: none"><li>- Aggregated volume</li><li>- Price</li></ul> |  |           |           |   |                         |   |   |
| e)        | Date of the transaction  | 2017-11-21 17:00 UTC+1   |           |           |   |                         |   |   |
| f)        | Place of the transaction   | Outside a trading venue  |           |           |   |                         |   |   |

|           |   |  |  |           |           |   |                         |   |   |
|-----------|---|--|--|-----------|-----------|---|-------------------------|---|---|
| 1         | Details of the Reporting Person / Closely Associated Person   |  |  |           |           |   |                         |   |   |
| a)        | Name  | Anders Vadsholt  |  |           |           |   |                         |   |   |
| 2         | Reason for the notification   |  |  |           |           |   |                         |   |   |
| a)        | Position/status   | Chief Financial Officer  |  |           |           |   |                         |   |   |
| b)        | Initial notification/Amendment  | Initial notification   |  |           |           |   |                         |   |   |
| 3         | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor  |  |  |           |           |   |                         |   |   |
| a)        | Name  | Orphazyme A/S  |  |           |           |   |                         |   |   |
| b)        | LEI code  | 54930025OZD2GGSQ7L42   |  |           |           |   |                         |   |   |
| 4         | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |  |  |           |           |   |                         |   |   |
| a)        | Description of the financial instrument, type of instrument and identification code   | Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S<br><br>ISIN DK0060910917  |  |           |           |   |                         |   |   |
| b)        | Nature of the transaction   | Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme                        |  |           |           |   |                         |   |   |
| c)        | Price(s) and volume(s)  | <table><tr><td>Price (s)</td><td>Volume(s)</td></tr><tr><td>0</td><td>4,000 (Matching shares)</td></tr><tr><td>0</td><td>16,000 (Performance shares assuming full vesting)</td></tr></table> |  | Price (s) | Volume(s) | 0 | 4,000 (Matching shares) | 0 | 16,000 (Performance shares assuming full vesting) |
| Price (s) | Volume(s)   |  |  |           |           |   |                         |   |   |
| 0         | 4,000 (Matching shares)   |  |  |           |           |   |                         |   |   |
| 0         | 16,000 (Performance shares assuming full vesting)   |  |  |           |           |   |                         |   |   |

|    |  |                         |
|----|--|-------------------------|
| d) | Aggregated information<br>- Aggregated volume<br>- Price |                         |
| e) | Date of the transaction                                  | 2017-11-21 17:00 UTC+1  |
| f) | Place of the transaction                                 | Outside a trading venue |

| <b>1</b>  | <b>Details of the Reporting Person / Closely Associated Person</b>   |  |           |           |   |                         |   |   |
|-----------|--|--|-----------|-----------|---|-------------------------|---|---|
| a)        | Name   | Thomas Kirkegaard Jensen   |           |           |   |                         |   |   |
| <b>2</b>  | <b>Reason for the notification</b>   |  |           |           |   |                         |   |   |
| a)        | Position/status  | Chief Scientific Officer   |           |           |   |                         |   |   |
| b)        | Initial notification/Amendment   | Initial notification   |           |           |   |                         |   |   |
| <b>3</b>  | <b>Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor</b>  |  |           |           |   |                         |   |   |
| a)        | Name   | Orphazyme A/S  |           |           |   |                         |   |   |
| b)        | LEI code   | 54930025OZD2GGSQ7L42   |           |           |   |                         |   |   |
| <b>4</b>  | <b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b> |  |           |           |   |                         |   |   |
| a)        | Description of the financial instrument, type of instrument and identification code  | Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S<br><br>ISIN DK0060910917  |           |           |   |                         |   |   |
| b)        | Nature of the transaction  | Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme  |           |           |   |                         |   |   |
| c)        | Price(s) and volume(s)   | <table border="1"> <thead> <tr> <th>Price (s)</th><th>Volume(s)</th></tr> </thead> <tbody> <tr> <td>0</td><td>4,000 (Matching shares)</td></tr> <tr> <td>0</td><td>16,000 (Performance shares assuming full vesting)</td></tr> </tbody> </table> | Price (s) | Volume(s) | 0 | 4,000 (Matching shares) | 0 | 16,000 (Performance shares assuming full vesting) |
| Price (s) | Volume(s)  |  |           |           |   |                         |   |   |
| 0         | 4,000 (Matching shares)  |  |           |           |   |                         |   |   |
| 0         | 16,000 (Performance shares assuming full vesting)  |  |           |           |   |                         |   |   |
| d)        | Aggregated information<br>- Aggregated volume<br>- Price   |  |           |           |   |                         |   |   |
| e)        | Date of the transaction  | 2017-11-21 17:00 UTC+1   |           |           |   |                         |   |   |
| f)        | Place of the transaction   | Outside a trading venue  |           |           |   |                         |   |   |

| <b>1</b>  | <b>Details of the Reporting Person / Closely Associated Person</b>   |   |           |           |   |                         |   |  |
|-----------|--|---|-----------|-----------|---|-------------------------|---|--|
| a)        | Name   | Thomas Blaettler  |           |           |   |                         |   |  |
| <b>2</b>  | <b>Reason for the notification</b>   |   |           |           |   |                         |   |  |
| a)        | Position/status  | Chief Medical Officer   |           |           |   |                         |   |  |
| b)        | Initial notification/Amendment   | Initial notification  |           |           |   |                         |   |  |
| <b>3</b>  | <b>Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor</b>  |   |           |           |   |                         |   |  |
| a)        | Name   | Orphazyme A/S   |           |           |   |                         |   |  |
| b)        | LEI code   | 54930025OZD2GGSQ7L42  |           |           |   |                         |   |  |
| <b>4</b>  | <b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b> |   |           |           |   |                         |   |  |
| a)        | Description of the financial instrument, type of instrument and identification code  | Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S<br><br>ISIN DK0060910917   |           |           |   |                         |   |  |
| b)        | Nature of the transaction  | Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme   |           |           |   |                         |   |  |
| c)        | Price(s) and volume(s)   | <table border="1"> <thead> <tr> <th>Price (s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>1,875 (Matching shares)</td> </tr> <tr> <td>0</td> <td>7,500 (Performance shares assuming full vesting)</td> </tr> </tbody> </table> | Price (s) | Volume(s) | 0 | 1,875 (Matching shares) | 0 | 7,500 (Performance shares assuming full vesting) |
| Price (s) | Volume(s)  |   |           |           |   |                         |   |  |
| 0         | 1,875 (Matching shares)  |   |           |           |   |                         |   |  |
| 0         | 7,500 (Performance shares assuming full vesting)   |   |           |           |   |                         |   |  |
| d)        | Aggregated information<br>- Aggregated volume<br>- Price   |   |           |           |   |                         |   |  |
| e)        | Date of the transaction  | 2017-11-21 17:00 UTC+1  |           |           |   |                         |   |  |
| f)        | Place of the transaction   | Outside a trading venue   |           |           |   |                         |   |  |

**For additional information, please contact**

**Orphazyme**

Anders Vadsholt, CFO

+45 28 98 90 55